key: cord-0948805-zkrxjy23 authors: Jorg, Tanis; Ellen, Vancutsem; Denis, Piérard; Ilse, Weets; Maria, Bjerke; Johan, Schiettecatte; Deborah, De Geyter title: Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays date: 2021-01-19 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115313 sha: f097af120d26ec11bc494c542e82b1a469edc1d9 doc_id: 948805 cord_uid: zkrxjy23 OBJECTIVES: To evaluate the diagnostic performances of SARS-CoV-2 IgG antibody immunoassays. METHODS: Following immunoassays were studied: Abbott's SARS-CoV-2 IgG assay, Diasorin's Liaison SARS-CoV-2 S2/S2 IgG assay, Euroimmun's Anti-SARS-CoV-2 IgG ELISA, and Roche's Elecsys Anti-SARS-CoV-2 assay. Specificity was retrospectively evaluated with 38 samples from 2019. Sensitivity samples (n = 147) were taken from SARS-CoV-2 real-time PCR-positive patients who developed COVID-19 symptoms 10 days earlier. RESULTS: Mean specificity was 96.6%. Mean sensitivity was 62.7% from 10 days after onset of symptoms, 84.4% from 15 days after onset of symptoms, and 87.5% from 20 days after onset of symptoms. CONCLUSIONS: Specificity was high, while Abbott and Roche were 100% specific. Sensitivity increased over time, with Abbott and Roche having the highest sensitivity at all time points with ≥ 90% from 20 days after symptoms' onset. These findings may assist in selecting SARS-CoV-2 IgG antibody immunoassays for additional diagnostics, epidemiological research, and vaccine development. Late 2019, a novel strain of coronavirus affecting primarily the respiratory system emerged. Being closely related to severe acute respiratory syndrome coronavirus (SARS-CoV), it was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From early 2020, the outbreak evolved into a pandemic of coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2 [1] . COVID-19 symptoms may vary in severity from having no symptoms to anosmia, rhinitis, sore throat, cough, fever, dyspnea, pneumonia, acute respiratory distress syndrome, sepsis, and septic shock, potentially fatal [2] . Currently, gold standard tests to diagnose COVID-19 are nucleic acid amplification tests (NAAT), such as polymerase chain reaction (PCR), on respiratory tract samples [3] . However, false negative results occur due to sampling errors or insufficient amounts of viral genome at the site of sample collection (e.g., in mild cases and from 8 days after onset of symptoms) [4] . Therefore, additional diagnostic methods are needed. Detection of antibodies in serum may be suitable after acute illness. Mild or even asymptomatic infections might also be more easily detected, which may be of epidemiological importance [5] . Most commonly used methods for detecting antibodies are immunoassays and lateral flow assays (LFA). Immunoassay is a laboratory-based method mostly performed with an appropriate automated analysis device, thereby achieving a high-throughput detection. LFA is suitable for point-of-care testing but has a lower throughput detection and is more labor intensive. Recently, several serological SARS-CoV-2 antibody assays have been developed and made available. Due to urgency, usually with limited validation (commissioned) by the developer. Therefore, we evaluated and compared the diagnostic performance of four immunoassays for the detection of SARS-CoV-2 IgG antibodies. This retrospective study was approved by the standing Committee on Ethics of the University Hospital Brussels. The study was conducted in the microbiology and chemistry laboratories of the University Hospital Brussels between May 7 and 26, 2020. All sera were left-over samples from blood samples taken for previous clinical examination and stored at ≤ -20 ºC in the hospital's laboratory. The SARS-CoV-2 IgG assay (Abbott Laboratories; #06R8620; 100 tests/kit; CE marked; for use on Architect i System) is a chemiluminescent microparticles immunoassay (CMIA) for qualitative detection of IgG antibodies to the nucleocapsid protein of SARS-CoV-2 in human serum or plasma using purified SARS-CoV-2 recombinant antigen coated microparticles. Following to the manufacturer's recommendations, the cut-off index (COI) was < 1.4 for a negative result and ≥ 1.4 for a positive result. The Liaison SARS-CoV-2 S2/S2 IgG assay (Diasorin S.p.A; #311450; 110 tests/kit; for use on Liaison XL Analyzer; CE marked) is a chemiluminescence immunoassay (CLIA) for quantitative detection of IgG antibodies to the S1/S2 domains from the SARS-CoV-2 spike proteins in human serum or plasma using magnetic beads coated with S1 and S2 antigens. Following to the manufacturer's recommendations, the cut-off value was < 12.0 AU/ml for a negative result, ≥ 12.0 to < 15.0 AU/ml for an equivocal result, and ≥ 15.0 AU/ml for a positive result. The Anti-SARS-CoV-2 ELISA IgG (Euroimmun AG; #El 2606-9601 G; 96 tests/kit; CE marked; for use on Eurolab Workstation ELISA Analyzer I-2P) is an enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgG antibodies to the S1 domain from the SARS-CoV-2 spike protein including the immunologically relevant receptorbinding domain in human serum or plasma using microplate wells coated with recombinant structural protein (S1 domain) of SARS-CoV-2. Following to the manufacturer's recommendations, the COI was < 0.8 for a negative result, ≥ 0.8 to < 1.1 for an equivocal result, and ≥ 1.1 for a positive result. The Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics GmbH; #09203079190; 300 tests/kit; CE marked; for use on Cobas e 801 Analyzer) is an electro-chemiluminescence immunoassay (ECLIA) based on a double-antigen sandwich principle for qualitative detection of antibodies (including IgG) to the nucleocapsid protein of SARS-CoV-2 in human serum and plasma using a recombinant protein representing the SARS-CoV-2 nucleocapsid antigen. Following to the manufacturer's recommendations, the COI was < 1.0 for a negative result and ≥ 1.0 for a positive result. The four studied immunoassays were performed according to the manufacturer's instructions. Specificity was determined from 38 samples. The total number of samples tested per assay differed slightly, because 4 samples had insufficient volume for testing all four immunoassays. Mean specificity was 96.6% (range 89.2 -100%). See Table 1 for specificity performance characteristics per immunoassay. [8] . The variation in sensitivity of the tested immunoassays may be partly due to the SARS-CoV-2 antigen targeted. Both immunoassays with the overall lowest sensitivity detect IgG antibodies to the S1 domain from the SARS-CoV-2 spike protein, while both immunoassays with the overall highest sensitivity detect IgG antibodies to the SARS-CoV-2 nucleocapsid protein. The viral spike protein is considered to be the preferred antigen, because it is very specific and because is the main antigen eliciting neutralizing antibodies [9] . However, the nucleocapsid protein being the most abundant viral protein is easier to detect and, although less specific than the viral spike protein, does not pose specificity problems based on our results. Even from 20 days after onset of symptoms, the best performing immunoassays´ sensitivity seems to be relatively low (90%). In part, this may be because not all COVID-19 patients produce antibodies [10] . This notion is supported by our results showing that negative tested samples frequently test negative across all four immunoassays. The samples were from hospitalized and critically ill patients, all of whom are expected to normally develop antibodies. Therefore, clinicians, future studies, and policy makers should take into account that not only patients with asymptomatic or mild COVID-19 may not develop SARS-CoV-2 IgG antibodies or show a rapid decay of these antibodies [12] , but also patients with severe COVID-19. In addition, our findings may assist in selecting appropriate SARS-CoV-2 IgG antibody immunoassays for vaccine development. However, more research is needed to determine to what extent such assays may be useful therein. After many infections, the development and persistent presence of IgG antibodies can be used as an immunity marker. However, because the kinetics of SARS-CoV-2 antibodies appear to be consistent with the kinetics of other coronaviruses and may therefore decline relatively quickly, SARS-CoV-2 antibodies may not be the most suitable outcome measure in the development of COVID-19 vaccines. Maybe it is better to use primarily T cell-mediated immunity markers. SARS-CoV-2 antibody assays, however, may still fulfill a secondary role in vaccine research, for example to gain insight into the (early) immune response more easily and quickly [13] . The present study is the first to evaluate and compare the four widely commercially available immunoassays for the detection of SARS-CoV-2 IgG antibodies of Abbott, Diasorin, Euroimmun, and Roche. Another strength is the authors' absence of conflicting interests; the independently obtained results from this study may assist others select the most appropriate immunoassay. A limitation of this study is the relatively small sample sizes. Especially, the results with regard to specificity are prone to errors due to chance findings because of the use of only 38 samples. In addition, cross-reactivity between SARS-CoV-2 and the four relatively harmless coronaviruses causing common cold could have been tested more closely by selecting samples with proven antibodies to such a coronavirus, but such samples are unfortunately not available since diagnosis of infections with these viruses is not standard practice. Furthermore, the specificity samples were collected between January 1 and December 26, 2019, relatively short before the spread of SARS-CoV-2 in Europe. In future research, it would be better to use seronegative samples collected at least several months before the first report of SARS-CoV-2 infections from China. Finally, the specificity samples did not contain any sera from SARS-CoV patients. Although SARS-CoV was never widespread in Europe and has not circulated in the population since 2003, it would have been scientifically interesting to test cross-reactivity with SARS-CoV samples [9] , because of the high degree of similarity between both the spike proteins and several nucleocapsid proteins of SARS-CoV and SARS-CoV-2 [14] . The present study shows that the four tested immunoassays for the detection of SARS-CoV-2 IgG antibodies all have a high degree of specificity. Their performances regarding sensitivity show more variance and even from 20 days after onset of symptoms, the best performing immunoassays´ sensitivity is only 90%. However, this relatively low degree of sensitivity may be partly due to a lack of production of antibodies in some COVID-19 patients. European Centre for Disease Prevention and Control. Event background COVID-19 World Health Organization Laboratory testing for coronavirus disease 2019 ( CO ID-19) in suspected human cases: interim guidance Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) IBM SPSS Statistics for Macintosh, version 26.0. Armonk: IBM Corp VassarStats: website for statistical computation Antibody tests for identification of current and past infection with SARS-Co -2. Cochrane Database of Systematic Reviews Developing antibody tests for SARS-CoV-2 Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19 Immunological considerations for COVID-19 vaccine strategies Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Writing -Original draft, Writing -Review & Editing, Visualization Conceptualization, Investigation, Resources, Writing -Review & Editing Conceptualization, Resources, Writing -Review & Editing, Supervision Weets Ilse: Resources, Writing -Review & Editing Bjerke Maria: Investigation, Resources Schiettecatte Johan: Investigation, Resources Conceptualization, Investigation, Writing -Review & Editing, Supervision The authors thank the involved laboratory technicians from the microbiology and chemistry laboratories of the University Hospital Brussels for their technical assistance. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.